"name","rationale","id","description","instanceType","label","uuid:ID"
"Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study","StudyDesign","","16476a07-472c-4a5e-88ff-d9166abe87e9"
